KR960037045A - Pharmaceutical preparations for the prevention and treatment of hepatitis B virus (HBV) - Google Patents

Pharmaceutical preparations for the prevention and treatment of hepatitis B virus (HBV) Download PDF

Info

Publication number
KR960037045A
KR960037045A KR1019950010214A KR19950010214A KR960037045A KR 960037045 A KR960037045 A KR 960037045A KR 1019950010214 A KR1019950010214 A KR 1019950010214A KR 19950010214 A KR19950010214 A KR 19950010214A KR 960037045 A KR960037045 A KR 960037045A
Authority
KR
South Korea
Prior art keywords
hepatitis
hbv
virus
prevention
treatment
Prior art date
Application number
KR1019950010214A
Other languages
Korean (ko)
Other versions
KR0141648B1 (en
Inventor
이종욱
유중근
이상호
Original Assignee
김태훈
주식회사 유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김태훈, 주식회사 유한양행 filed Critical 김태훈
Priority to KR1019950010214A priority Critical patent/KR0141648B1/en
Priority to AU55164/96A priority patent/AU5516496A/en
Priority to JP8532384A priority patent/JPH09508150A/en
Priority to EP96912312A priority patent/EP0766560A1/en
Priority to PCT/KR1996/000056 priority patent/WO1996033711A2/en
Priority to CN96190391A priority patent/CN1152259A/en
Publication of KR960037045A publication Critical patent/KR960037045A/en
Application granted granted Critical
Publication of KR0141648B1 publication Critical patent/KR0141648B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)로 표시되는 티오케텐 유도체 또는 이들의 무독성 염을 유효성분으로 함유하고 약제학적으로 허용가능한 첨가제를 함유하는 B형 바이러스(HBV)성 간염의 예방 및 치료용 약학적 제제에 관한 것이다.The present invention is a pharmaceutical for the prevention and treatment of hepatitis B virus (HBV) hepatitis B containing a thioketene derivative represented by the following general formula (I) or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable additive To a red formulation.

여기서, Y는 -CH2- 또는 -CH=CH-이며, A는 NH 또는 O이고, R1은 C1-C4의 직쇄상 또는 분지상 알킬이다. A가 0일때, R2는 C1-C4의 직쇄상 또는 분지상 알킬이고, A가 NH일때, R2는 벤질, 2-피리딜, 2-티아졸릴, 4-메틸리아졸-2-일, 4-카르복시티아졸-2-일, 또는 1,3,4-티아디아졸-2-일이다.Wherein Y is —CH 2 — or —CH═CH—, A is NH or O and R 1 is C 1 -C 4 straight or branched alkyl. When A is 0, R 2 is C 1 -C 4 straight or branched alkyl, and when A is NH, R 2 is benzyl, 2-pyridyl, 2-thiazolyl, 4-methylazol-2- One, 4-carboxythiazol-2-yl, or 1,3,4-thiadiazol-2-yl.

Description

B형 바이러스(HBV)성 간염의 예방 및 치료용 약학적 제제Pharmaceutical preparations for the prevention and treatment of hepatitis B virus (HBV)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (3)

하기 일반식(Ⅰ)로 표시되는 티오케텐 유도체 또는 이들의 무독성 염을 유효성분으로 함유하고 약제학적으로 허용가능한 첨가제를 함유하는 B형 바이러스(HBV)성 간염의 예방 및 치료용 약학적 제제.A pharmaceutical preparation for the prevention and treatment of hepatitis B virus (HBV) hepatitis B, which contains a thioketene derivative represented by the following general formula (I) or a nontoxic salt thereof as an active ingredient and a pharmaceutically acceptable additive. 여기서, Y는 -CH2- 또는 -CH=CH-이며, A는 NH 또는 O이고, R1은 C1-C4의 직쇄상 또는 분지상 알킬이다. A가 0일때, R2는 C1-C4의 직쇄상 또는 분지상 알킬이고, A가 NH일때, R2는 벤질, 2-피리딜, 2-티아졸릴, 4-메틸티아졸-2-일, 4-카르복시티아졸-2-일, 또는 1,3,4-티아디아졸-2-일이다.Wherein Y is —CH 2 — or —CH═CH—, A is NH or O and R 1 is C 1 -C 4 straight or branched alkyl. When A is 0, R 2 is C 1 -C 4 straight or branched alkyl, and when A is NH, R 2 is benzyl, 2-pyridyl, 2-thiazolyl, 4-methylthiazole-2- One, 4-carboxythiazol-2-yl, or 1,3,4-thiadiazol-2-yl. 제1항에 있어서, Y는 -CH2-이며, A는 NH이고, R1은 에틸 또는 이소프로필이며, R2는 벨질, 2-피리딜, 2-티아졸릴, 4-메틸티아졸-2일, 4-카르복시티아졸-2-일, 또는 1,3,4-티아디아졸-2-일인 것을 특징으로 하는 B형 바이러스(HBV)성 간염의 예방 및 치료용 약학적 제제.The compound of claim 1, wherein Y is —CH 2 —, A is NH, R 1 is ethyl or isopropyl, R 2 is benzyl, 2-pyridyl, 2-thiazolyl, 4-methylthiazole-2 1, 4-carboxythiazol-2-yl, or 1,3,4-thiadiazol-2-yl. A pharmaceutical preparation for the prevention and treatment of hepatitis B virus (HBV) hepatitis. 제1항에 있어서, Y는 -CH=CH-이며, A는 NH이고, R1은 이소프로필이며, R2는 벤질, 2-피리딜, 4-메틸티아졸-2일, 또는 1,3,4-티아디아졸-2-일인 것을 특징으로 하는 B형 바이러스(HBV)성 간염의 예방 및 치료용 약학적 제제.The compound of claim 1, wherein Y is —CH═CH—, A is NH, R 1 is isopropyl, R 2 is benzyl, 2-pyridyl, 4-methylthiazol-2yl, or 1,3 Pharmaceutical preparation for the prevention and treatment of hepatitis B virus (HBV) hepatitis, characterized in that, 4-thiadiazol-2-yl. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950010214A 1995-04-28 1995-04-28 Pharmaceutical composition for the treatment of b-type hepatis KR0141648B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1019950010214A KR0141648B1 (en) 1995-04-28 1995-04-28 Pharmaceutical composition for the treatment of b-type hepatis
AU55164/96A AU5516496A (en) 1995-04-28 1996-04-26 Use of thioketene derivatives for preventing or treating hep atitis b
JP8532384A JPH09508150A (en) 1995-04-28 1996-04-26 Use of thioketene derivative for prevention or treatment of hepatitis B
EP96912312A EP0766560A1 (en) 1995-04-28 1996-04-26 Use of thioketene derivatives for preventing or treating hepatitis b
PCT/KR1996/000056 WO1996033711A2 (en) 1995-04-28 1996-04-26 Use of thioketene derivatives for preventing or treating hepatitis b
CN96190391A CN1152259A (en) 1995-04-28 1996-04-26 Use of thioketene derivatives for preventing or treating hepatitis B

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950010214A KR0141648B1 (en) 1995-04-28 1995-04-28 Pharmaceutical composition for the treatment of b-type hepatis

Publications (2)

Publication Number Publication Date
KR960037045A true KR960037045A (en) 1996-11-19
KR0141648B1 KR0141648B1 (en) 1998-06-01

Family

ID=19413186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950010214A KR0141648B1 (en) 1995-04-28 1995-04-28 Pharmaceutical composition for the treatment of b-type hepatis

Country Status (6)

Country Link
EP (1) EP0766560A1 (en)
JP (1) JPH09508150A (en)
KR (1) KR0141648B1 (en)
CN (1) CN1152259A (en)
AU (1) AU5516496A (en)
WO (1) WO1996033711A2 (en)

Also Published As

Publication number Publication date
KR0141648B1 (en) 1998-06-01
AU5516496A (en) 1996-11-18
EP0766560A1 (en) 1997-04-09
WO1996033711A2 (en) 1996-10-31
JPH09508150A (en) 1997-08-19
CN1152259A (en) 1997-06-18

Similar Documents

Publication Publication Date Title
KR950017957A (en) Preparation and intermediates of 3, 4, 4-trisubstituted-piperidinyl-N-alkylcarboxylates
DE69206876T2 (en) Antivirus preparations containing nucleoside analogs
KR910011896A (en) Novel Glycopeptide Derivatives
NO963053D0 (en) Cosmetic or pharmaceutical preparations containing mangiferin or derivatives thereof
KR890016966A (en) New antiviral agents
ATE321543T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROXIMIC ACID DERIVATIVES
FI921522A0 (en) PYRAZOLOPYRIDINFOERENING OCH FOERFARANDE FOER DESS FRAMSTAELLNING.
KR950017949A (en) Water-soluble inclusions of benzothiophene compounds and water-soluble cyclodextrins, pharmaceutical preparations and methods for their preparation
PT630252E (en) PREPARATION OF RAMNOLIPID-BASED PHARMACEUTICAL AGAINST DERMATOLOGICAL DISEASES
KR910004191A (en) Renal disease treatment
KR900009606A (en) Fluorine-containing 2-nitroimidazole derivatives and radiation sensitizers containing them
KR920012110A (en) Oxidized Glutathione Alkyl Ester
TR200000153T2 (en) 6-azauracil derivatives that inhibit il-5.
KR900001715A (en) BU-3608 derivative
KR880008801A (en) Solution for parenteral administration
IL93594A0 (en) Pharmaceutical compositions containing an imidazopyrimidone derivative
KR880002822A (en) Cerebral Ischemia Prevention Treatment
BR0112338A (en) Compound, pharmaceutical composition, and use of a compound
KR960037045A (en) Pharmaceutical preparations for the prevention and treatment of hepatitis B virus (HBV)
ATE285771T1 (en) ANTI-CANCER COMPOSITION CONTAINING DIAMINOTRIFLUOROMETHYLPYRIMIDENE DERIVATIVES
HU9203849D0 (en) Thiazole derivatives
KR900701262A (en) Treatment for Pancreatitis
KR890008121A (en) Rhodanine Derivatives and Pharmaceutical Compositions
NZ246598A (en) Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds
KR980002033A (en) Triazole derivatives or salts thereof

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020215

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee